Cite
The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma.
MLA
Rathi, Vinay K., et al. “The Inflation Reduction Act: Implications for Medicare Spending and Access to Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyposis and Asthma.” International Forum of Allergy & Rhinology, vol. 14, no. 7, July 2024, pp. 1261–65. EBSCOhost, https://doi.org/10.1002/alr.23344.
APA
Rathi, V. K., Soler, Z. M., Schlosser, R. J., Workman, A. D., Chapurin, N., Rowan, N. R., & Dusetzina, S. B. (2024). The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma. International Forum of Allergy & Rhinology, 14(7), 1261–1265. https://doi.org/10.1002/alr.23344
Chicago
Rathi, Vinay K., Zachary M. Soler, Rodney J. Schlosser, Alan D. Workman, Nikita Chapurin, Nicholas R. Rowan, and Stacie B. Dusetzina. 2024. “The Inflation Reduction Act: Implications for Medicare Spending and Access to Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyposis and Asthma.” International Forum of Allergy & Rhinology 14 (7): 1261–65. doi:10.1002/alr.23344.